Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
Rhea-AI Summary
Inari Medical (NASDAQ: NARI) announced that data from the PEERLESS trial will be presented at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium on October 29th. The trial is a prospective, randomized controlled study comparing outcomes of patients with intermediate-risk pulmonary embolism treated with Inari's FlowTriever system versus catheter-directed thrombolysis.
The primary endpoint is a win-ratio analysis of clinical and hospital resource utilization outcomes. Dr. Wissam Jaber from Emory University School of Medicine will present the findings during the Late-Breaking Clinical Trial Sessions. This study aims to provide critical information on optimal treatment for PE patients and is the first of several RCTs Inari is conducting in the VTE space.
Positive
- PEERLESS trial data to be presented at a prestigious scientific symposium (TCT 2024)
- First randomized controlled trial comparing FlowTriever to a historical PE treatment option
- Study may provide critical information for optimal PE patient treatment
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, NARI declined 1.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.
The PEERLESS trial is a prospective, randomized controlled trial (“RCT”) comparing the outcomes of patients with intermediate-risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis. The primary endpoint is a win-ratio analysis of important clinical and hospital resource utilization outcomes. This study will provide critical information to clinicians on the optimal treatment for PE patients.
“PEERLESS is the first RCT directly comparing FlowTriever to a historical treatment option for PE and is the first of several RCTs that Inari is bringing to the VTE space,” said Dr. Thomas Tu, Inari’s Chief Medical Officer. “Patients and physicians deserve high-quality clinical evidence to inform treatment choices and we are thrilled to see this study be presented at TCT.”
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
IR@inarimedical.com
FAQ
What is the PEERLESS trial for Inari Medical (NARI)?
When and where will the PEERLESS trial data for Inari Medical (NARI) be presented?
What is the primary endpoint of Inari Medical's (NARI) PEERLESS trial?
Who will present the PEERLESS trial data for Inari Medical (NARI)?
